The project has completed the production workshop of anti-tumor drugs, including three workshops of non-sterile raw materials, oral solid preparations (tablets, capsules), injections (non-terminal sterile injections, freeze-dried powder injections), warehousing, QC laboratory system and supporting infrastructure, and obtained the EU certification for the production technology of anti-tumor drugs in November 2019, including stability, efficacy, etc. Increasing investment in research and development, introducing high-end foreign and domestic experts, developing urgently needed anti-tumor products in the market, and striving to market and sell anti-tumor drugs as soon as possible is one of the new treatment fields that the company plans to focus on. With the increase of tumor incidence rate, its market expansion is accelerating, and it has good growth potential. Its international market share is the largest in the overall drug market, and its domestic market share is second only to anti infective drugs, It will soon become the first treatment field. Our company chooses to develop anti-tumor drugs in order to provide high-quality and low-cost anti-tumor drugs for the majority of patients. Antitumor drugs are one of the new therapeutic fields that the company plans to focus on. With the increase of the incidence rate of cancer, its market has a good growth potential. The international market has the largest share of the overall drug market, and the domestic market share is second only to anti infective drugs. It will soon become the largest therapeutic field. Our company chooses to develop anti-tumor drugs in order to provide high-quality and low-cost anti-tumor drugs for the majority of patients.